Isosorbide-based aspirin prodrugs: Integration of nitric oxide releasing groups

Journal of Medicinal Chemistry

Volumn 52, Issue 21, 2009, Pages 6588-6598

  Jones, Michael ^a   Inkielewicz, Iwona ^a,b   Medina, Carlos ^a   Santos Martinez, Maria Jose ^a   Radomski, Anna ^a   Radomski, Marek W ^a   Lally, Maeve N ^a   Moriarty, Louise M ^a   Gaynor, Joanne ^a   Carolan, Ciaran G ^a   Khan, Denise ^a   O'Byrne, Paul ^a   Harmon, Shona ^a   Holland, Valerie ^a   Clancy, John M ^a   Gilmer, John F ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; ESTER DERIVATIVE; ISOSORBIDE; ISOSORBIDE 2 ASPIRINATE 5 (2 METHYLBENZOATE); ISOSORBIDE 2 ASPIRINATE 5 (2 NITROXYMETHYL)BENZOATE; ISOSORBIDE 2 ASPIRINATE 5 (3 HYDROXYBENZOATE); ISOSORBIDE 2 ASPIRINATE 5 (3 METHYLBENZOATE); ISOSORBIDE 2 ASPIRINATE 5 (3 NITROOXYMETHYL)BENZOATE; ISOSORBIDE 2 ASPIRINATE 5 (4 HYDROXYBENZOATE); ISOSORBIDE 2 ASPIRINATE 5 (4 METHYL 1,2,3 THIADIAZOLE 5 OATE); ISOSORBIDE 2 ASPIRINATE 5 (4 NITROOXYMETHYL)BENZOATE; ISOSORBIDE 2 ASPIRINATE 5 [1 METHYL (1H) PYRAZOLE 5 CARBOXYLATE]; ISOSORBIDE 2 ASPIRINATE 5 ACETATE; ISOSORBIDE 2 ASPIRINATE 5 BENZOATE; ISOSORBIDE 2 ASPIRINATE 5 CYCLOPROPANOATE; ISOSORBIDE 2 ASPIRINATE 5 ESTER; ISOSORBIDE 2 ASPIRINATE 5 ISO NICOTINATE; ISOSORBIDE 2 ASPIRINATE 5 NICOTINATE; ISOSORBIDE 2 ASPIRINATE 5 PENTANOATE; ISOSORBIDE 2 ASPIRINATE 5 PROPIONATE; ISOSORBIDE 2ASPIRNATE 5 (4 PHENYLBENZOATE); ISOSORBIDE 5 MONONITRATE 2 ASPIRINATE; ISOSORBIDE 5 NITRATE; NITRATE; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HYDROLYSIS; THROMBOCYTE AGGREGATION;

ASPIRIN; BUTYRYLCHOLINESTERASE; ESTERS; HUMANS; HYDROLYSIS; ISOSORBIDE; MODELS, MOLECULAR; NITRATES; NITRIC OXIDE DONORS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 71049183971     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900561s     Document Type: Article

References (41)

1. (a) Roth, G. J.; Stanford, N.; Majerus, P. W. Acetylation of prostaglandin synthase by aspirin. Proc. Natl. Acad. Sci. U.S.A 1975, 72, 3073-3076.
2. (b) Patrono, C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 1994, 330, 1287-1294.
3. Romano, M. Lipid mediators: lipoxin and aspirin-triggered 15-epilipoxins. Inflamm. Allergy Drug Targets 2006, 5, 81-90. (Pubitemid 43796670)
4. Flossmann, E.; Rothwell, P. M. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. British Doctors Aspirin Trial and the UKTIA Aspirin Trial. Lancet 2007, 369, 1603-1613.
5. Imaeda, A. B.; Watanabe, A.; Sohail, M. A.; Mahmood, S.; Mohamadnejad, M.; Sutterwala, F. S.; Flavell, R. A.; Mehal, W. Z. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J. Clin. Invest. 2009, 119, 305-314.
6. Breitner, J. C. S. The role of anti-inflammatory drugs in the prevention and treatment of Alzheimer's disease. Annu. Rev. Med. 1996, 47, 401-411.
7. (a) Serrano, P.; Lanas, A.; Arroyo, M. T.; Ferreira, I. J. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment. Pharmacol. Ther. 2002, 16, 1945-1953.
8. (b) Kurata, J. H.; Abbey, D. E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalisation. J. Clin. Gastroenterol. 1990, 12, 260-266.
9. (c) Cryer, B.; Luk, G.; Feldman, M. Effects of very low doses of aspirin (ASA) on gastric, duodenal and rectal prostaglandins (PGs) & mucosal injury. Gastroenterology 1995, 108, A77.
10. Loke, Y. K.; Bell, A.; Derry, S. Aspirin for the prevention of cardiovascular disease: calculating benefit and harm in the individual patient. Br. J. Clin. Pharmacol. 2003, 55, 282-287.
11. Kelly, J. P.; Kaufman, D. W.; Jurgelon, J. M.; Sheehan, J.; Koff, R. S.; Shapiro, S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996, 348, 1413-1416. (Pubitemid 26395236)
12. Van Oijen, M. G.; Dieleman, J. P.; Laheij, R. J.; Sturkenboom, M. C.; Jansen, J. B.; Verheugt, F. W. Peptic ulcerations are related to systemic rather than local effects of low-dose aspirin. Clin. Gastroenterol. Hepatol. 2008, 6, 309-313.
13. Ligumsky, M.; Golanska, E. M.; Hansen, D. G.; Kauffman, G. L. Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in the rat. Gastroenterology 1983, 84, 756-761.
14. Cooke, A. R.; Goulston, K. Failure of intravenous aspirin to increase gastrointestinal blood loss. Br. Med. J. 1969, 4, 330-332.
15. Elwood, P. C.; Gallagher, A. M.; Duthie, G. G.; Mur, L. A.; Morgan, G. Aspirin, salicylates, and cancer. Lancet 2009, 373, 1301-1309
16. (a) Del Soldato, P.; Sorrentino, R.; Pinto, A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 1999, 20, 319-323.
17. (b) Gresele, P.; Momi, S. Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. Cardiovasc. Drug Rev. 2006, 24 (2), 148-168
18. Elliott, S. N.; Wallace, J. L. Nitric oxide: a regulator of mucosal defense and injury. J. Gastroenterol. 1998, 33, 792-803. (Pubitemid 29271539)
19. Minuz, P.; Lechi, C.; Zuliani, V.; Gaino, S.; Tommasoli, R.; Lechi, A. NO-aspirins: anti-thrombotic activity of derivatives of acetyl-salicylic acid releasing nitric oxide. Cardiovasc. Drug Rev. 1998, 16, 31-47.
20. Cena, C; Lolli, M. L.; Lazzarato, L; Guaita, E; Morini, G; Coruzzi, G; McElroy, S. P.; Megson, I. L.; Fruttero, R; Gasco, A. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J. Med. Chem. 2003, 46, 747-754.
21. Velázquez, C. A.; Chen, Q. H.; Citro, M. L.; Keefer, L. K.; Knaus, E. E. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)-diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2008, 51, 1954-1961.
22. Lazzarato, L.; Donnola, M.; Rolando, B.; Marini, E.; Cena, C.; Coruzzi, G.; Guaita, E.; Morini, G.; Fruttero, R.; Gasco, A.; Biondi, S.; Ongini, E. Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid. J. Med. Chem. 2008, 51, 1894-1903.
23. Nielsen, N. M.; Bungaard, H. Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. J. Med. Chem. 1989, 32, 727-734.
24. Gilmer, J. F.; Moriarty, L. M.; Clancy, J. M. Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitroaspirins. Bioorg. Med. Chem. Lett. 2007, 17, 3217-3220
25. Moriarty, L. M.; Lally, M. N.; Carolan, C. G.; Jones, M.; Clancy, J. M.; Gilmer, J. F. Discovery of a "true" aspirin prodrug. J. Med. Chem. 2008, 51, 7991-7999.
26. (a) Gilmer, J. F.; Moriarty, L. M.; McCafferty, D. F.; Clancy, J. M. Synthesis, hydrolysis kinetics and anti-platelet effects of isosorbide mononitrate derivatives of aspirin. Eur J. Pharm. Sci. 2001, 14, 221-227.
27. (b) Gilmer, J. F.; Murphy, M. A.; Shannon, J. A.; Breen, C. G.; Ryder, S. A.; Clancy, J. M. Single oral dose study of two isosorbide-based aspirin prodrugs in the dog. J. Pharm. Pharmacol. 2003, 55, 1351-1357.
28. Bundgaard, H.; Nielsen, N. M. Glycolamide esters as a novel biolabile prodrug type for nonsteroidal anti-inflammatory carboxylic acid drugs. Int. J. Pharm. 1988, 43, 101-110.
29. (a) Torfgard, K. E.; Ahlner, J. Mechanisms of action of nitrates. Cardiovasc. Drugs Ther. 1994, 8, 701-717.
30. (b)Wendt, R. L. Systemic and coronary vascular effects of the 2- and 5-mononitrate esters of isosorbide dinitrate. J. Pharmacol. Exp. Ther. 1972, 180, 732-742.
31. La Du, B. N.; Snady, H. Esterases of human tissues. Handb. Exp. Pharmacol. 1971, 28, 477-499.
32. Burton, D. J.; Koppes, W. M. Cleavage of carboxylic acid esters to acid chlorides with dichlorotriphenylphosphorane. J. Org. Chem. 1975, 40, 3026-3032.
33. Carolan, C. G.; Gaynor, J. M.; Dillon, G. P.; Khan, D.; Ryder, S.; Reidy, S. A.; Gilmer, J. F. Novel isosorbide di-ester compounds as inhibitors of acetylcholinesterase. Chem.-Biol. Interact. 2008, 175, 293-297.
34. Chaney, A.; Wolfrom, M. Notes; An Attempted Synthesis of Phenyl Nitrate. J. Org. Chem. 1961, 26, 2998.
35. Weber, A. A.; Strobach, H; Schror, K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur. J. Pharmacol. 1993, 247, 29-37.
36. Gilmer, J. F.; Lally, M. N.; Gardiner, P.; Dillon, G.; Gaynor, J. M.; Reidy, S. Novel isosorbide-based substrates for human butyryl-cholinesterase. Chem. - Biol. Interact. 2005, 157-158, 317-319.
37. Carolan, C. G.; Dillon, G. P.; Gaynor, J. M.; Reidy, S.; Ryder, S. A.; Khan, D.; Marquez, J. F.; Gilmer, J. F. Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors. J. Med. Chem. 2008, 51, 6400-6409.
38. Nicolet, Y.; Lockridge, O.; Masson, P.; Fontecilla-Camps, J. C.; Nachon, F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J. Biol. Chem. 2003, 278, 41141-41147.
39. Luo, W.; Yu, Q. S.; Kulkarni, S. S.; Parrish, D. A.; Holloway, H. W.; Tweedie, D.; Shafferman, A.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine. J. Med. Chem. 2006, 49, 2174-2185.
40. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithmand an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662.
41. Ellman, G. L.; Courtney, K. D.; Andres, V.; Featherstone, R. M. A New and Rapid Colorimetric Determination of Acetylcholinesterase Activity. Biochem. Pharmacol. 1961, 7, 88-95.